Recombinant Human CD86 protein, C-hFc-Avi Tag, Biotinylated

Product Description

Cat

IMP-090

Official Symbol

CD86

Product Overview

Biotinylated Recombinant Human CD86 protein(AA Leu 26-Pro 247)(Accession # AAH40261) is expressed from human 293 cells (HEK293). This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag.

Expression System

HEK293

Species

Human

Tag

C-hFc-Avi Tag

Form

Lyophilized from sterile Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose.

Conjugate

Biotinylated

Molecular Mass

The protein has a calculated MW of 53.8 kDa. As a result of glycosylation, the protein migrates as 66-100 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE).

Protein length

Leu 26-Pro 247

Endotoxin

Less than 1.0 EU per ug by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.

Reconstitution

It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4ºC before opening to recover the entire contents.

Bioactivity-FACS Title 2

Bioactivity-FACS

SDS-PAGE

Biotinylated Human B7-2, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA 1

Immobilized Human CTLA-4, Fc Tag at 5 ug/mL (100 uL/well) can bind Biotinylated Human B7-2, Fc,Avitag with a linear range of 19-156 ng/mL.

Bioactivity-ELISA 2

Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag: Biotinylated Human B7-2, Fc,Avitag binding reactions. The half maximal inhibitory concentration (IC50) is 0.1701 ug/mL.

Bioactivity-FACS 1

Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 ug/mL.

Bioactivity-FACS 2

FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 ug/mL. The IC50 is 0.031 ug/mL.

Bioactivity-FACS 3

Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-2 is 2 ug/mL.

Bioactivity-FACS 4

FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-2 is 2 ug /mL. The IC50 is 1.014 ug/mL.

Data Sheet MSDS

Datasheet MSDS

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Online Inquiry